HAN by Centers for Disease Control and Prevention (U.S.)
This is an official
CDC HEALTH ADVISORY
Distributed via Health Alert Network
Sunday, July 25, 2010, 22:35 EDT (10:35 PM EDT)
CDCHAN-00315-2010-07-25-ADV-N
Increased Potential for Dengue Infection in Travelers Returning from 
International and Selected Domestic Areas
Summary
Dengue virus transmission has been increasing to epidemic levels in many parts of the tropics and 
subtropics. Travelers to these areas are at risk of acquiring dengue virus and developing dengue fever 
(DF) or the severe form of the disease, dengue hemorrhagic fever (DHF). The Centers for Disease 
Control and Prevention (CDC) strongly advises that health care providers in the United States should: 1) 
consider DF and DHF when evaluating patients returning from dengue-affected areas--both domestic and 
abroad--who present with an acute febrile illness within two weeks of their return, 2) submit serum 
specimens for appropriate laboratory testing, and 3) report all presumptive and confirmed cases of DF 
and DHF to their local or state health department.
Background
Dengue transmission has been increasing to epidemic levels in many parts of the tropics and subtropics 
where it had previously been absent or mild. Dengue-affected areas are widely distributed throughout 
Africa, Asia, Pacific, the Americas and the Caribbean. This calendar year, more than 50 countries have 
reported evidence of dengue transmission; including 17 countries in Asia, 17 in the Americas, 10 in 
Africa, seven in the Caribbean, and one in the Pacific. With an extensive dengue outbreak occurring in 
Puerto Rico and evidence of continued transmission in Key West, Florida, travel to certain domestic 
locations may also pose a risk for the traveler. The mosquitoes known to transmit dengue virus, Aedes 
aegypti and Aedes albopictus, are present throughout much of the southeastern United States and 
infected returning travelers may pose a risk for initiating local transmission.
Symptoms
Dengue virus infections can manifest as a subclinical infection or DF, and may develop into potentially 
fatal DHF. DF is a self-limited febrile illness that is characterized by high fever plus two or more of the 
following: headache, retro-orbital pain, joint pain, muscle or bone pain, rash, mild hemorrhagic 
manifestations (e.g., bleeding of nose or gums, petechiae, or easy bruising), and leukopenia. Because 
the incubation period for dengue infection ranges from 3 to 14 days, the patient may not present with 
illness until after returning from travel. Clinical management of DF consists of symptomatic treatment 
(avoid aspirin, NSAIDS and corticosteroids, as they can promote hemorrhage) and monitoring for the
development of severe disease at or around the time of defervescence. A small proportion of patients 
develop DHF, which is characterized by presence of resolving fever or a recent history of fever, lasting 
2-7  days, any hemorrhagic manifestation, thrombocytopenia (platelet count <100,000/mm3), and 
increased vascular permeability, evidenced by hemoconcentration, hypoalbuminemia or hypoproteinemia, 
ascites, or pleural effusion. DHF can result in circulatory instability or shock. Adequate management 
requires timely recognition and hospitalization, close monitoring of hemodynamic status, and judicious 
administration of intravascular fluids. There is no antiviral drug or vaccine against the dengue virus. 
Updated guidelines for the management of dengue can be found at 
http://whqlibdoc.who.int/publications/2009/9789241547871_eng.pdf
• Health care providers seeing patients with dengue-like illness who have recently traveled to Puerto 
Rico, Key West, Florida or international dengue-affected areas (See world distribution of dengue 
maps at http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-5/dengue-fever-dengue-hemorrhagic- 
fever.aspx) should report cases to the local or state health department and send specimens for 
laboratory testing. DF and DHF are now nationally notifiable conditions in the United States. Please 
remember that apart from individuals traveling for tourism, individuals responding to international 
disasters (e.g., Haiti earthquake), participating in medical or religious missionary work, and visiting 
friends and relatives are often returning from dengue-affected areas and should be evaluated for 
dengue infection if they present with dengue-like illness during or after their travel.
• Reporting to local public health officials and consideration of hospitalization to initiate supportive care 
should not be delayed pending test results. Reporting suspected dengue cases will trigger a public 
health investigation and the implementation of prevention measures.
• Specimens from patients with acute febrile illness, who returned from dengue-affected areas within 
the past 14 days, should be submitted to their local or state health department, if the health 
department laboratory offers dengue testing. State health departments with the capacity to test for 
dengue include: AZ, CA, CT, FL, NY, PR, and TX.
• If the local or state health department does not perform dengue testing, submit specimens directly to 
CDC laboratories in San Juan, Puerto Rico (address below). CDC offers free diagnostic testing for 
health care providers and confirmatory dengue testing for health department and private laboratories. 
A completed CDC Dengue Case Investigation Form
(http://www.cdc.gov/Dengue/resources/DCIF_English_ColorSept1508_FINAL_.pdf) must accompany 
the specimens for the appropriate testing to be performed.
Whenever possible, submit paired acute and convalescent specimens (2 ml of centrifuged serum.) 
Accuracy is increased when both acute and convalescent specimens are available for testing. But 
providers should not wait and should submit acute specimens as soon as available; a convalescent 
specimen can be submitted when available.
Type of sample
Interval since onset of 
symptoms
Type of Analysis
Acute until day 5 RT-PCR for dengue virus
Convalescent 6 to 30 days ELISA for dengue IgM
Centers for Disease Control and Prevention
Dengue Branch
1324 Cañada Street
San Juan, Puerto Rico 00920
Tel: (787) 706-2399; fax (787) 706-2496
For More Information:
• Criteria for the processing of dengue samples at the CDC Dengue Branch is available at: 
http://www.cdc.gov/Dengue/resources/TestpolEng_2.pdf.
• Additional information about dengue is available at: http://www.cdc.gov/dengue/
• Call CDC's toll-free information line, 800-CDC-INF0 (800-232-4636) TTY: (888) 232-6348, which is 
available 24 hours a day, every day.
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